keytruda side effects
keytruda side effects, Keytruda (pembrolizumab) is a monoclonal antibody (immunotherapy) indicated for the treatment of people with: advanced (unresectable or metastatic) melanoma
metastatic nonsquamous NSCLC as first-line treatment in combination with pemetrexed and carboplatin recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
recurrent classical Hodgkin Lymphoma (cHL) locally advanced or metastatic urothelial carcinoma
solid tumours having the biomarkers MSI-H or dMMR recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.
How does Keytruda (pembrolizumab) work?
Indeed Keytruda (pembrolizumab) has been designed to attach to and block a receptor called ‘programmed cell death-1’ (PD-1), which switches off the activity of certain cells of the immune system (the body’s natural defences) called T cells.
By blocking PD-1, pembrolizumab prevents PD-1 from switching off these immune cells, thereby increasing the ability of the immune system to kill cancer cells1. Buy Keytruda Online here at cancercureonlinestore.com
Where has Keytruda (pembrolizumab) been approved?
keytruda side effects
Food and Drug Administration (FDA), USA:
September 4, 2014, for advanced or unresectable melanoma
October 2, 2015, for advanced (metastatic) NSCLC which progressed after other treatments and with tumours that express a protein called PD-L14
August 8, 2016, for recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HBSCC)
October 24, 2016, as first-line treatment for metastatic NSCLC with PD-L1 expression on ≥ 50 % of cells as determined by an FDA-approved test; in absence of EGFR or ALK genomic tumour aberrations, and for patients with metastatic NSCLC whose tumours express PD-L1 on ≥ 1 % of cells with disease progression on or after platinum-containing chemotherapy.
March 14, 2017, for adult and pediatric patients with refractory cHL, or who have relapsed after 3 or more prior lines of therapy
May 10, 2017, in combination with pemetrexed and carboplatin, as first-line treatment for metastatic nonsquamous NSCLC
September 22, 2017, for patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (PD-L1 Combined Positive Score (CPS) ≥1), with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu-targeted therapy
European Medical Agency (EMA), European Union:
July 17, 2015, for advanced or unresectable melanoma
June 23, 2016, for locally advanced or metastatic NSCLC
January 31, 2017, as first-line treatment of patients with metastatic NSCLC with PD-L1 on ≥50% of cells and without EGFR or ALK mutation8,9
May 2017, for relapsed or refractory classical Hodgkin lymphoma (cHL)
July 20, 2017, for locally advanced or metastatic urothelial carcinoma17
Therapeutic Goods Administration (TGA), Australia:
April 16, 2015, for advanced melanoma for relapsed or refractory classical Hodgkin Lymphoma (cHL) for locally advanced or metastatic urothelial carcinoma3
. If you have a question about its approval in a specific country feel free to contact our support team.
How is Keytruda (pembrolizumab) taken?
- Another key point which is standard dosage
Melanoma: 200 mg every 3 weeks
NSCLC: 200 mg every 3 weeks
HNSCC: 200 mg every 3 weeks
cHL: 200 mg every 3 weeks for adults and 2 mg/kg (up to 200 mg) every 3 weeks for pediatrics
Urothelial Carcinoma: 200 mg every 3 weeks
MSI-H Cancer: 200 mg every 3 weeks for adults and 2 mg/kg (up to 200 mg) every 3 weeks for children
Gastric Cancer: 200 mg every 3 weeks.
Administer as an intravenous infusion over 30 minutes.
First thing to remember: Please consult with your treating doctor for personalized dosing.
- in fact the most common adverse reactions ( ≥20% of patients) listed in the prescribing information include1,2,3:
Serious adverse reactions On the negative side and on the positive side
The serious adverse reactions listed in the prescribing information include
Type 1 diabetes mellitus
immune-mediated skin adverse reactions including, StevensJohnson syndrome (SJS) and toxic epidermal necrolysis (TEN)
Other immune-mediated adverse reactions: In organ transplant recipients
Complications of allogeneic HSCT.
Use in a specific population
Keytruda (pembrolizumab) can be fatal for a fetus; it is not advised for women who are pregnant or breast feeding
Avoid use in patients with a severely damaged immune system
For a comprehensive list of side effects and adverse reactions please refer to the official prescribing information click here